Brief: Eloxx Pharmaceuticals Announces Submission Of Investigational New Drug Application For Zkn-013
28/03/2023 23:31
March 28 (Reuters) - Eloxx Pharmaceuticals Inc ELOX.O :
* ELOXX PHARMACEUTICALS ANNOUNCES SUBMISSION OF
INVESTIGATIONAL
NEW DRUG (IND) APPLICATION FOR ZKN-013
* ELOXX PHARMACEUTICALS ANNOUNCES SUBMISSION OF
INVESTIGATIONAL
NEW DRUG (IND) APPLICATION FOR ZKN-013
* ELOXX PHARMACEUTICALS INC - ADDITIONAL IND FILING FOR
ZKN-013
FOR TREATMENT OF FAMILIAL ADENOMATOUS POLYPOSIS EXPECTED IN
FIRST HALF OF 2023
Source text for Eikon: ID:nGNX8CbKPS
Further company coverage: ELOX.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Eloxx Pharmaceuticals
See all newsNASDAQ RESUMED AT 02:24 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:19 PM
Brief: Eloxx Pharmaceuticals Provides ELX-02 And ZKN-013 Program Updates
Brief: Eloxx Pharmaceuticals Confirms That Alport Syndrome Patients Treated With Elx-02 In Phase 2 Study Had Improvement
Brief: Eloxx Pharmaceuticals Inc Reports Results In All Patients Treated With Elx-02 In Phase 2 Clinical Study For Alport Syndrome